Published in Nucl Med Rev Cent East Eur on January 01, 2002
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2008) 5.29
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Effect of fractionation in stereotactic body radiation therapy using the linear quadratic model. Int J Radiat Oncol Biol Phys (2012) 2.00
Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res (2005) 1.77
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol (2005) 1.46
Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1beta mRNA. FEBS J (2009) 1.44
Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg (2007) 1.42
Welcome to thyroid research. Thyroid Res (2008) 1.40
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol (2004) 1.31
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer (2005) 1.15
Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol (2010) 1.13
SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab (2013) 1.12
Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol (2005) 1.08
Inhibition of tumor growth by plant-derived mAb. Proc Natl Acad Sci U S A (2005) 1.08
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
Genome-wide association study on differentiated thyroid cancer. J Clin Endocrinol Metab (2013) 1.03
Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab (2007) 1.02
Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol (2004) 1.02
How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys (2002) 0.99
Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med (2007) 0.98
Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett (2004) 0.98
Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. Thyroid (2005) 0.98
Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol (2012) 0.97
Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys (2006) 0.96
A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer (2007) 0.95
DNA damage and repair in lymphocytes of normal individuals and cancer patients: studies by the comet assay and micronucleus tests. Acta Biochim Pol (2003) 0.95
Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr Rev (2007) 0.95
Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol (2009) 0.93
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc Natl Acad Sci U S A (2006) 0.92
13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res (2009) 0.92
VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Med Sci Monit (2012) 0.91
Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine (2007) 0.91
Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One (2010) 0.90
Association between age at diagnosis of Graves' disease and variants in genes involved in immune response. PLoS One (2013) 0.90
Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res (2009) 0.90
Idiopathic hypertrophic pachymeningitis - case report and literature review. Folia Neuropathol (2007) 0.89
Sneddon's syndrome as a disorder of small arteries with endothelial cells proliferation: ultrastructural and neuroimaging study. Folia Neuropathol (2005) 0.88
Plant-derived EpCAM antigen induces protective anti-cancer response. Cancer Immunol Immunother (2007) 0.88
BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. Front Biosci (Elite Ed) (2011) 0.88
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer (2014) 0.87
Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal. BMC Genomics (2009) 0.87
Small cerebral vessel disease in familial amyloid and non-amyloid angiopathies: FAD-PS-1 (P117L) mutation and CADASIL. Immunohistochemical and ultrastructural studies. Folia Neuropathol (2007) 0.86
Gene expression profile of human thyroid cancer in relation to its mutational status. J Mol Endocrinol (2011) 0.86
Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study. Folia Neuropathol (2008) 0.86
Granular cell astrocytoma. A case report with immunohistochemical and ultrastructural characterization. Folia Neuropathol (2008) 0.86
Radiation-related changes in serum proteome profiles detected by mass spectrometry in blood of patients treated with radiotherapy due to larynx cancer. J Radiat Res (2011) 0.86
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. J Clin Endocrinol Metab (2014) 0.86
Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1*07. Thyroid (2006) 0.85
NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma. Folia Histochem Cytobiol (2009) 0.85
Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy. Acta Neurochir Suppl (2010) 0.84
Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt) (2006) 0.84
Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. Int Arch Allergy Immunol (2009) 0.84
Hypofractionated stereotactic radiotherapy for large or involving critical organs cerebral arteriovenous malformations. Radiol Oncol (2013) 0.84
Radiation-induced DNA damage and its repair in lymphocytes of patients with head and neck cancer and healthy donors. Anticancer Res (2002) 0.84
Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab (2006) 0.84
Changes in cerebral hemodynamics assessed by transcranial Doppler ultrasonography in children after head injury. Childs Nerv Syst (2002) 0.83
Giant cell ependymoma of the spinal cord and fourth ventricle coexisting with syringomyelia. Folia Neuropathol (2008) 0.83
Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. Biochim Biophys Acta (2004) 0.83
Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci (2012) 0.83
Epidural hematomas in a child with Hutchinson-Gilford progeria syndrome. Childs Nerv Syst (2002) 0.83
Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res (2010) 0.83
Intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy : treatment feasibility and preliminary results. Strahlenther Onkol (2010) 0.82
Increase in activity of neutrophils and proinflammatory mediators in rats following acute and prolonged focal cerebral ischemia and reperfusion. Acta Neurochir Suppl (2010) 0.82
Intraoperative monitoring of cochlear function using distortion product otoacoustic emissions (DPOAEs) in patients with cerebellopontine angle tumors. Otol Neurotol (2004) 0.82
Role of nuclear medicine imaging in differential diagnosis of accessory spleens in patients after splenectomy. Pol J Radiol (2012) 0.81
Modeling and biomechanical analysis of craniosynostosis correction with the use of finite element method. Int J Numer Method Biomed Eng (2012) 0.81
[Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi]. Endokrynol Pol (2006) 0.81
Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Med Genomics (2013) 0.81
Somatostatin receptors in human adrenal gland tumors--immunohistochemical study. Folia Histochem Cytobiol (2008) 0.81
Immunization with a plant-produced colorectal cancer antigen. Cancer Immunol Immunother (2003) 0.80
[Gene expression profile of medullary thyroid carcinoma--preliminary results]. Endokrynol Pol (2006) 0.80
Surgical approaches to pathological lesions of the middle cerebellar peduncle and the lateral part of the pons - clinical observation. Neurol Neurochir Pol (2007) 0.80
MR spectroscopic evaluation of brain tissue damage after treatment for pediatric brain tumors. Acta Neurochir Suppl (2010) 0.80
Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors. Pol J Pathol (2004) 0.80
Endoscopic transsphenoidal treatment of hormonally active pituitary adenomas. Neuro Endocrinol Lett (2007) 0.80
Amyloid angiopathy in idiopathic Parkinson's disease. Immunohistochemical and ultrastructural study. Folia Neuropathol (2008) 0.80
[Completion total thyroidectomy in children with differentiated thyroid cancer]. Endokrynol Pol (2006) 0.80